ORGANOGENESIS HOLDINGS INC (ORGO)
US68621F1021 - Common Stock
ORGANOGENESIS HOLDINGS INC
NASDAQ:ORGO (5/3/2024, 2:29:50 PM)
2.525
+0.03 (+1.41%)
Company Profile
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 1,030 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier for a variety of wound types, and the Affinity, Novachor and NuShield wound coverings to address a variety of wound sizes and types. Its sports medicine products include NuShield for surgical application in soft tissue repairs, and Affinity, Novachor and PuraPly AM for management of open wounds in the surgical setting. The company offers its products to a range of healthcare customers, including hospitals, wound care centers and physician offices.
Company Info
ORGANOGENESIS HOLDINGS INC
85 Dan Rd
Canton MASSACHUSETTS 02021
P: 17815750775
CEO: Gary S. Gillheeney Sr.
Employees: 1030
Website: https://investors.organogenesis.com
ORGO News
8 days ago - ChartmillLet's take a look at the stocks that are in motion in today's session.What's going on in today's session
8 days ago - ChartmillWhat's going on in today's sessionIntrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
8 days ago - ChartmillThursday's session: gap up and gap down stocksThere are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
11 days ago - Market News VideoCommit To Purchase Organogenesis Holdings At $2.50, Earn 33.2% Annualized Using OptionsCANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the...
CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company’s motion to dismiss all claims asserted.
ORGO Twits
Here you can normally see the latest stock twits on ORGO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
